Ensysce Biosciences (ENSC) investor relations material

Company overview and business model

• Cy Biopharma acquisition closed August 5, 2026; the resulting pipeline includes CY200, a clinical-stage, psilocybin-predominant botanical oral therapy for Type 1 Complex Regional Pain Syndrome (CRPS).

• CY200 uses a 5-HT2A serotonin-receptor and neuroplastogenic approach targeting neural circuitry associated with severe chronic and complex pain; its active ingredient received FDA Orphan Drug Designation.

Financial performance and metrics

• Smaller reporting company status reflects non-affiliate market value below $700 million and annual revenue below $100 million in the most recently completed FY.

• Audited 2025 and 2024 financial statements include going-concern uncertainty: Baker Tilly cited uncertainty for the registrant, and EisnerAmper cited substantial doubt about Cy Biopharma's ability to continue as a going concern.

Use of proceeds and capital allocation

• Net proceeds from the Securities Purchase Agreement and milestone-based Side Letter Agreements are expected to advance Cy's technology platform.

• Selling securityholders receive all resale proceeds; registration expenses are borne by the issuer, while sellers bear their sale commissions, discounts and disposal expenses.